1027338-34-6

Usage

Uses

Used in Pharmaceutical Synthesis:
1-AminoMethyl-1-(Boc-Amino)Cyclopropane, 97% is used as a key building block in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures. The Boc protection allows for selective reactions to occur at other sites on the molecule, facilitating the creation of diverse drug candidates.
Used in Organic Synthesis:
In the field of organic synthesis, 1-AminoMethyl-1-(Boc-Amino)Cyclopropane, 97% serves as an intermediate for the preparation of a range of biologically active molecules. Its cyclopropane ring and protected amino functionality make it a versatile component in the construction of intricate organic compounds.
Used in Research Applications:
Due to its high purity and unique chemical properties, 1-AminoMethyl-1-(Boc-Amino)Cyclopropane, 97% is also used in research settings to explore new reaction pathways, develop novel synthetic methods, and investigate the properties of cyclopropane-containing compounds.
Used in Industrial Applications:
1-AMinoMethyl-1-(Boc-aMino)cyclopropane, 97%'s high purity and stability make it suitable for use in industrial applications where consistent and reliable performance is required. It can be employed in the large-scale production of pharmaceuticals and other specialty chemicals that require cyclopropane-based structures.

Upstream product

• 849149-60-6 tert-butyl [1-(azidomethyl)cyclopropyl]carbamate 
• 1429913-33-6 {1-[(tert-butoxycarbonyl)amino]cyclopropyl}methyl 4-methylbenzenesulfonate 
• 1354226-66-6 tert-butyl {1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]cyclopropyl}carbamate 
• 107259-06-3 tert-butyl (1-formylcyclopropyl)carbamate 
• 107017-74-3 (1-((tert-butoxycarbonyl)amino)cyclopropyl)methyl methanesulfonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 107017-73-2 tert-butyl (1-(hydroxymethyl)cyclopropyl)carbamate 

Downstream Products

• 143842-25-5 1-Amino-1-(aminomethyl)cyclopropane 
• 1392310-67-6 4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1-(tert-butoxycarbonylamino)cyclopropyl)methylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid 
• 1392314-11-2 methyl 4-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-((1-(tert-butoxycarbonylamino)cyclopropyl)methylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate 

Relevant academic research and scientific papers

Synthesis of spirocyclopropanated analogues of imidacloprid and thiacloprid

tert-Butyl N-[1-(hydroxymethyl)cyclopropyl]carbamate (8) was converted into spirocyclopropanated analogues 14-CP and 14-CT of the insecticide Thiacloprid (2) in six simple steps with overall yields of 24 % each, along with their regioisomers 13-CP and 13-CT in overall yields of 17 and 15 %, respectively. The spirocyclopropanated analogues 27-CP and 27-CT of the insecticide Imidacloprid (1) were prepared from 8 in five steps in an overall yield of 10 % each, along with their regioisomers 20-CP and 20-CT in an overall yield of 8 and 7 %, respectively. The key step in all preparations was a cocyclization of an appropiately protected (1-aminocyclopropyl)methyl derivative with S,S-dimethyl cyanodithioimino-carbonate (11) or nitroguanidine (22). The structures of several final products and by-products were verified by X-ray crystal structure analyses.

Heterocyclic compound serving as SOS1 inhibitor

The invention provides a compound serving as an SOS1 inhibitor, and particularly provides a compound with a structure as shown in a formula (I), or an optical isomer, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative, a hydrate and a solvate of the compound. The compound can be used for treating or preventing diseases or symptoms related to the activity or expression quantity of SOS1.

ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS

Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.

ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS

The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition comprising said compound.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.